New Generation, Targeting Rare and Refractory Mutations of EGFR
Small molecule NSCLC Phase I Global Oncology/Cancer
Boston
|
San Jose
|
Newark
|
Frankfurt
London
|
Basel
|
Beijing
|
Shanghai
Hangzhou
|
Suzhou
Stay Connected and Get Updates
Subscribe newsletter